Authorizing Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy11514

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2015-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE       Parliamentary submission
DATE             2017-08-18
TOPICS           Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act

https://policybase.cma.ca/link/policy13861

POLICY TYPE: Parliamentary submission
DATE: 2018-04-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)

https://policybase.cma.ca/link/policy13726

POLICY TYPE: Policy endorsement
DATE: 2017-05-26
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2010-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Cannabis for Medical Purposes

CMA POLICY

Links:
- The Canadian Medical Association (CMA) recognizes the unique requirements of those individuals suffering from terminal illness or chronic disease for which conventional therapies have not been effective or are contra-indicated (or appear to be).
- Persons have a right to refuse or discontinue treatment at any time for medical reasons, and the need
- Note: for individuals using cannabis for medical reasons, instructions should be given on the
- Note: in some provinces, written consent from patients and their doctors should be documented for medical purposes.
- The NTP's poppy growing licence for medical purposes is as follows:
- The NTP's poppy growing licence for medical purposes is as follows:

The CMA endorses the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis. The NTP should encourage the development of guidelines for patients, health care professionals, and industry.
2. Support the research and development of new cannabinoid products to improve the quality, availability, and accessibility of cannabis products.
3. Increase support for the education of patients and health care professionals about the medical use of cannabis.

For the latest information on cannabis for medical purposes, visit https://policybase.cma.ca/link/policy10045
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE  Parliamentary submission
DATE  2017-04-07
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
CMA’s recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the Senate Standing Committee on Social Affairs, Science and Technology

April 7, 2017
CMA's Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE
Parliamentary submission

DATE
2018-02-15

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Excise duty framework for cannabis products

https://policybase.cma.ca/link/policy13799

POLICY TYPE  Response to consultation
DATE  2017-12-07
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight
https://policybase.cma.ca/link/policy14125

POLICY TYPE: Response to consultation
DATE: 2019-09-03
TOPICS: Health care and patient safety
        Population health, health equity, public health

Documents
The Health risks and harms associated with the use of marijuana

https://policybase.cma.ca/link/policy11138

POLICY TYPE  Parliamentary submission
DATE  2014-05-27
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE
Response to consultation

DATE
2016-08-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana
Legalization and Regulation

August 29, 2016

STATEMENT | DÉCLARATION

Choi Isabelle - application d’herbe

Objective: To provide a summary of the CMA’s position on the legalization, regulation and restriction of access to marijuana, as well as to outline the potential implications for medical practitioners.

The CMA believes that the legalization of marijuana should be accompanied by robust education and awareness campaigns. This is important to ensure that the public understands the potential health risks associated with marijuana use.

In terms of regulation, the CMA supports the creation of a regulated marketplace for marijuana, similar to that of any other pharmaceutical product. This would allow for better control over the quality and safety of the product, as well as provide a mechanism for taxation.

The CMA is concerned about the potential impact of marijuana legalization on young people. It is important to implement effective strategies to prevent youth from accessing marijuana, including education and targeted public health campaigns.

In conclusion, the CMA’s position is that the legalization of marijuana should be accompanied by comprehensive education, regulation, and measures to protect the health of Canadians.

For further information, please contact: info@policybase.cma.ca

CMA Policybase - Canadian Medical Association
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE
Response to consultation

DATE
2018-01-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents